Compare 10X Genomics Inc (TXG) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Yum! Brands, Inc. — how do they compare? 10X Genomics Inc trades at $47.2 (market cap $5.48B), while Yum! Brands, Inc. trades at $148 (market cap $40.62B). The key difference: Yum! Brands, Inc. is far larger — about 7.4× 10X Genomics Inc's market cap, and Yum! Brands, Inc. pays a 2.04% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | YUM | |
|---|---|---|
Market Cap | $5.48B | $40.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $45.80 | $168.16 |
52-Week Low | $11.34 | $138.21 |
Enterprise Value | $5.02B | $51.88B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
YUM trades at $147.10, down 0.55% amid a cyclosporiasis outbreak linked to Taco Bell lettuce. Technicals are bearish with key support at $145, while fundamentals show steady revenue growth to $8.21B in 2025 and a net margin of 20.48%. The company maintains strong cash flow from operations of $2.01B but carries high long-term debt of $11.25B.
Despite near-term headwinds from food safety concerns, YUM's diversified brand portfolio and consistent profitability support a positive long-term outlook. Analyst consensus price target of $177 suggests 20% upside, but investors should monitor outbreak resolution and Q2 2026 earnings due soon.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
